Efficacy of Recombinant Human Interferon α-2b Vaginal Effervescent Capsule Combined with Baofukang Suppository in the Treatment of Cervical Precancerous Lesions with High-risk HPV Infection
Objective To explore the clinical value of recombinant human interferon α-2b vaginal effervescent capsule(RHIα2b-VEC)combined with Baofukang suppository in the treatment of cervical precancerous lesions(CIN)complicated with high-risk human papillomavirus(HPV)infection.Methods A total of 66 patients with CIN complicated with high-risk HPV infection admitted to Taihe County Maternal and Child Health Family Planning Service Center from July 2020 to January 2023 were collected and divided into control group(33 patients)and observation group(33 patients)by random number table method.The control group was treated with Baofukang suppository,and the observation group was treated with RHIα2 b-VEC on the basis of the control group.The HPV clearance efficacy,comprehensive efficacy,serum inflammatory indexes[interleukin-4(IL-4),interleukin-12(IL-12)],T lymphocyte levels(CD8+,CD4+,CD4+/CD8+)and adverse reactions were compared between the two groups.Results The effective rate of HPV clearance in the observation group was 63.64％,which was higher than 39.39％in the control group(P＜0.05).The effective rate of comprehensive treatment in the observation group was 60.61％,which was higher than 33.33％in the control group(P＜0.05).After treatment,the levels of IL-4 and CD8+in the observation group were lower than those in the control group,and the levels of IL-12,CD4+and CD4+/CD8+in the observation group were higher than those in the control group(P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion RHIα2b-VEC combined with Baofukang suppository is effective in the treatment of CIN complicated with high-risk HPV infection,which can improve the negative conversion effect of HPV,regulate cytokines,improve immune function,and do not increase the incidence of adverse reactions.
万方数据
维普
